Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention – real life assessment

Paweł Bogacki, Anna Kabłak-Ziembicka, Krzysztof Bryniarski, Leszek Wrotniak, Elżbieta Ostrowska-Kaim, Krzysztof Żmudka, Tadeusz Przewłocki

Advances in Interventional Cardiology · 2016 · 16 citations · 27 references

DOIFull text

Open access

Concepts

Abstract

INTRODUCTION: Triple anticoagulation therapy (TT), comprising dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC), is essential in atrial fibrillation (AF) patients after percutaneous coronary intervention (PCI), but it increases the bleeding risk. AIM: To assess TT models, in- and out-hospital bleeding and thromboembolic complications, and TT alterations. MATERIAL AND METHODS: During 12 months, consecutive AF post-PCI patients were scheduled for TT. Alterations in TT and thromboembolic events (death, myocardial infarction, ischemic stroke, in-stent thrombosis, peripheral embolization) were recorded. Major, non-major and minor bleeding episodes were assessed. RESULTS: = 0.89). CONCLUSIONS: Our study indicates that TT is associated with high mortality and bleeding rates in a relatively short period of time. Discontinuation of any TT drug did not increase the thromboembolic event rate, while it was associated with reduced risk of major bleeding.

References

27